Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Endocrinology and metabolism indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Subclinical hypothyroidism

Endocrinology and metabolism · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Subclinical hypothyroidism does not itself cause an acute thyroid emergency. Urgently reassess the diagnosis when free T4 is low, there is hypothermia or physiological compromise, pituitary disease is possible, or pregnancy is confirmed, because those situations follow different pathways.

Overview

Confirm a persistent raised-TSH normal-free-T4 pattern, estimate likelihood of progression and benefit, and use treatment trials or surveillance without medicalising transient results.

The label describes biochemistry, not a symptom syndrome. TSH can rise temporarily during recovery from illness, after thyroiditis, because of medicines, after missed levothyroxine doses or through assay interference. A normal free T4 distinguishes this pattern from overt primary hypothyroidism, while central hypothyroidism generally does not present with a clearly raised TSH proportional to hormone deficiency.

Treatment decisions balance progression risk and plausible benefit against lifelong tablet burden and iatrogenic thyrotoxicosis. TSH at least 10 mIU/L is more likely to persist and progress than a mild elevation. Autoimmune evidence, prior destructive treatment and symptoms strengthen the case, but symptoms such as tiredness and weight change remain nonspecific.

A time-limited levothyroxine trial is an experiment with a predefined outcome, not automatic permanent therapy. Agree which symptoms will be reviewed, normalise TSH safely, and stop if there is no meaningful benefit. This approach prevents dose escalation from replacing investigation of sleep disturbance, anaemia, mood disorder, menopause or other common explanations.

Key points

  • Subclinical hypothyroidism is a persistently raised TSH with free T4 inside the assay reference range after transient and analytical causes are excluded.

Aetiology

01

Early autoimmune thyroid failure

Progressive autoimmune loss of thyroid reserve raises TSH before free T4 falls outside its reference interval.

02

Previous thyroid injury

Surgery, radioiodine or destructive thyroiditis can leave limited gland reserve and a persistent compensated biochemical pattern.

03

Transient or treatment-related elevation

Recovery from illness, missed levothyroxine, medicines, assay interference and physiological variation can raise TSH without enduring gland failure.

Pathophysiology

  1. 1
    Thyroid reserve declines

    The gland needs stronger pituitary stimulation to maintain free thyroid hormone within the laboratory range as the process continues.

  2. 2
    TSH rises through feedback

    A small reduction in thyroid-hormone effect produces a larger compensatory TSH increase while circulating free T4 remains normal.

  3. 3
    The pattern may persist or resolve

    Autoimmune or destructive disease can progress, whereas illness recovery and temporary interference may normalise on repeat testing.

  4. 4
    Treatment can overshoot

    Levothyroxine given without clear persistent need may suppress TSH and create atrial, skeletal or symptomatic thyrotoxic effects.

Clinical features and red flags

Persistent biochemical pattern

TSH remains above the laboratory upper limit while free T4 is normal on appropriately spaced samples, with no acute illness, major medicine change or credible assay problem explaining the finding.

Higher progression likelihood

TSH at least 10, positive TPO antibodies, goitre, previous thyroid surgery or radioiodine, and a rising trend make continuing primary thyroid failure more likely than an isolated minor elevation.

Possible symptom association

Cold intolerance, constipation, dry skin, menstrual change, cognitive slowing and fatigue may support a trial in an eligible younger adult, but symptoms must be documented and competing causes explored.

Overt disease insteadRed flag

A free T4 below range means overt hypothyroidism, not subclinical disease. Marked clinical deterioration, hypothermia, bradycardia or reduced consciousness requires urgent evaluation regardless of an earlier mild profile.

Special physiological contextRed flag

Known pregnancy, trying to conceive or assisted reproduction changes the risk-benefit calculation and reference ranges; arrange prompt obstetric or endocrine advice instead of waiting three months routinely.

Iatrogenic excess

Palpitations, tremor, insomnia, heat intolerance or a suppressed TSH during therapy suggests over-replacement, which is especially hazardous in older people and those with cardiac or osteoporosis risk.

Investigations

  1. 01
    Repeat TSH and free T4First step
    Why
    Confirm persistence and exclude evolution to overt deficiency.
    Interpretation and limitations
    For stable non-pregnant adults, two abnormal TSH results about three months apart underpin treatment decisions; a low free T4 reclassifies the condition as overt hypothyroidism.
  2. 02
    Thyroid peroxidase antibodies
    Why
    Estimate whether autoimmune thyroid disease underlies the raised TSH.
    Interpretation and limitations
    A positive test supports persistent autoimmune failure and closer follow-up, but repeating antibody concentrations adds no useful control information.
  3. 03
    Medication and supplement review
    Why
    Identify reversible physiology, adherence problems or analytical interference.
    Interpretation and limitations
    Lithium, amiodarone, iodine exposure and some immunotherapies can affect the axis; missed replacement doses and high-dose biotin require a tailored repeat plan.
  4. 04
    Pregnancy testing where relevant
    Why
    Prevent use of non-pregnant thresholds in early gestation.
    Interpretation and limitations
    A confirmed pregnancy triggers gestation- and assay-specific assessment with prompt specialist input; routine adult surveillance intervals are inappropriate.
  5. 05
    Focused alternative-cause screen

Differential diagnosis

01

Transient illness recovery

TSH can rebound after acute illness; repeating when physiologically stable avoids assigning a chronic thyroid diagnosis prematurely.

02

Poor levothyroxine adherence

Missed tablets followed by recent resumption can produce raised TSH with a misleadingly normal free T4.

03

Assay interference

Heterophile antibodies, macro-TSH or another assay-specific interference can produce a TSH result inconsistent with symptoms and free thyroid hormone measurements.

04

Central hypothyroidism

Low free T4 with a non-raised or biologically inappropriate TSH indicates pituitary disease, not the subclinical primary pattern.

Management

01ConfirmationValidate the subclinical labelFirst stepA stable adult has raised TSH with free T4 within range.+
  1. 1Review acute illness, pregnancy possibility, medicines, supplements, prior thyroid treatment and the magnitude and chronology of TSH elevation.
  2. 2Repeat TSH and free T4 after approximately three months in the routine pathway, adding TPO antibodies once when autoimmune disease status is informative.
  3. 3Reclassify promptly if free T4 becomes low, and refer when results suggest pituitary disease, assay interference or another complex explanation.
02TSH ten or moreConsider sustained replacementTSH is at least 10 mIU/L on two tests three months apart.+
  1. 1Discuss symptoms, age, comorbidity, pregnancy plans, progression likelihood, daily administration and the uncertainty of individual symptom benefit.

Complications

01

Progression to overt hypothyroidism

Persistent autoimmune loss can eventually lower free T4 and produce clearer metabolic, cardiovascular and reproductive consequences.

02

Adverse lipid profile

Reduced thyroid effect may worsen atherogenic lipids, particularly when TSH elevation is sustained and other vascular risks coexist.

03

Pregnancy-related risk

Thyroid physiology and treatment thresholds differ in pregnancy, so an unreviewed outpatient label can lead to under- or overtreatment.

04

Iatrogenic thyrotoxicosis

Unnecessary or excessive levothyroxine can suppress TSH, causing palpitations and increasing atrial-fibrillation and bone-loss risk over time.

Monitoring and follow-up

  • After starting or changing levothyroxine, follow TSH at an interval long enough for steady state and then approximately every three months until stable.
  • Once replacement is stable, annual TSH is generally sufficient unless symptoms, adherence, interacting medicines or pregnancy change the situation.
  • During a six-month therapeutic trial, track the agreed symptom outcomes as well as biochemistry; normal TSH without improvement argues against continuing solely for symptoms.
  • When untreated but autoimmune or structurally damaged thyroid disease is likely, measure TSH and free T4 annually to detect progression.
  • In low-risk untreated cases, arrange thyroid tests every two to three years and give the patient a route for earlier clinical reassessment.
  • Watch for treatment-related palpitations, atrial arrhythmia and bone-risk implications, especially when TSH falls below range.

Special situations

A threshold is not a mandate

TSH at least 10 strengthens the case for treatment, but confirmation, age, comorbidity, patient priorities and special settings still shape the final decision.

Trials need stopping rules

Naming target symptoms before levothyroxine begins makes it possible to judge benefit; otherwise normal day-to-day variation can turn a trial into permanent therapy.

Antibodies predict, not titrate

TPO antibody positivity signals autoimmune substrate and progression risk, while serial titres do not tell clinicians how much levothyroxine to prescribe.

Age changes net benefit

Minor TSH elevation is common in older populations, while overtreatment carries immediate rhythm and longer-term skeletal hazards; restraint can be active care.

Pregnancy is another algorithm

Maternal and fetal considerations, gestation-specific intervals and time-sensitive targets mean even a mild abnormality needs prompt review outside the general-adult pathway.

Common pitfalls

  1. 01

    Starting lifelong treatment from one mildly raised TSH after an intercurrent infection.

  2. 02

    Using nonspecific fatigue as proof that the biochemical finding caused symptoms.

  3. 03

    Forgetting to measure free T4 and thereby missing progression to overt disease.

  4. 04

    Escalating levothyroxine until TSH is suppressed because weight has not changed.

  5. 05

    Repeating TPO antibody titres as though they were a treatment target.

  6. 06

    Applying the under-65 six-month trial recommendation to every older adult.

  7. 07

    Waiting three months in a newly pregnant patient instead of seeking prompt specialist advice.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Endocrinology and metabolismOriginal SBA

Persistent higher TSH threshold

A non-pregnant adult has TSH 12 mIU/L twice, three months apart, with normal free T4 and no transient explanation. What option best reflects NICE guidance?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Endocrinology and metabolism topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG145 subclinical hypothyroidism recommendationsConfirmation, treatment thresholds, symptom trials and surveillance intervals.
  • BNF levothyroxine prescribing informationAdministration, cautions, interactions and dose adjustment.
  • NICE CKS hypothyroidism guidanceClinical assessment and primary-care monitoring context.
  • MHRA levothyroxine product-switch adviceRegulatory advice when symptoms follow switching between products.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
  • Confirm the abnormality on two samples separated by about three months before treatment in a stable non-pregnant adult, unless a different urgent context applies.
  • NICE advises considering levothyroxine when TSH is 10 mIU/L or higher on two measurements three months apart.
  • For symptomatic adults under 65 with TSH above range but below 10, NICE supports considering a six-month therapeutic trial after repeat confirmation.
  • Age, symptoms, previous radioiodine or surgery, goitre and thyroid peroxidase antibody positivity modify the chance that a raised TSH reflects persistent thyroid disease.
  • If symptoms do not improve once TSH is within range during a treatment trial, consider stopping levothyroxine and look for alternative causes rather than escalating indefinitely.
  • Untreated patients with features suggesting underlying thyroid disease usually need annual TSH and free T4; those without such features may be checked every two to three years.
  • Pregnancy, planned conception and fertility treatment use separate obstetric-endocrine thresholds and should not be managed from the ordinary adult algorithm.
  • In older adults, mild TSH elevation is more often transient and treatment can cause harm through over-replacement, atrial fibrillation and bone loss.
    • Why
    Investigate symptoms that may not be thyroid-mediated.
    Interpretation and limitations
    Use history to select full blood count, ferritin, B12, coeliac serology, renal or liver tests, sleep assessment and mental-health review rather than ordering a universal panel.
  • 06
    Lipid and cardiovascular risk assessment
    Why
    Quantify modifiable vascular risk when TSH elevation persists.
    Interpretation and limitations
    Dyslipidaemia can coexist, particularly with higher TSH, but treat cardiovascular risk on its own merits and do not promise levothyroxine will replace standard prevention.
    • 2
    When treatment is chosen, start levothyroxine using age and cardiovascular-risk principles and titrate TSH into the reference range without suppression.
  • 3Review response and safety at appropriate intervals; if treatment is declined, establish surveillance and clear triggers for earlier retesting.
    • 03TSH below tenRun a defined symptom trialAn adult under 65 has persistent mild elevation plus symptoms plausibly related to hypothyroidism.+
    1. 1Agree two or three specific symptoms and baseline severity, while checking anaemia, sleep, mood, menopause and other likely contributors.
    2. 2Offer a six-month levothyroxine trial after shared decision-making, adjusting carefully until TSH is within range and avoiding biochemical excess.
    3. 3If symptoms persist despite a normal TSH, consider stopping treatment, monitor thereafter and redirect evaluation to more likely diagnoses.
    04SurveillanceObserve without losing follow-upPreferredTreatment is not indicated, not beneficial or not preferred.+
    1. 1Check TSH and free T4 annually when TPO antibodies, previous thyroid intervention or another feature indicates underlying thyroid disease.
    2. 2Use a two-to-three-year interval when there are no underlying-disease features, with earlier testing if symptoms evolve or medicines change.
    3. 3Provide an explicit pregnancy-planning instruction and advise urgent review for marked deterioration rather than waiting for the scheduled blood test.
    Key medicines and prescribing safety1 treatment · regimens, roles and cautions+
    Lowers TSH and may improve attributable symptoms or reduce progression in selected patients.

    Levothyroxine for persistent subclinical hypothyroidism

    Select an individual once-daily starting dose using age, body size, TSH elevation and cardiovascular disease; titrate in small steps against TSH and the current BNF rather than using a universal regimen.

    Benefit is uncertain for mild asymptomatic disease, particularly in older adults. Separate from absorption interactions, avoid suppressed TSH, and use a specialist pregnancy pathway.